Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Initiates Passive Stake in Horizon Pharma Inc (HZNP)

James E. Flynn‘s healthcare-focused Deerfield Management has revealed, in a new filing with the SEC, initiating a passive stake in Horizon Pharma Inc (NASDAQ:HZNP). Deerfield owns around 4.4 million shares of the company, equal to 6.7% of the company’s common stock. The value of the position amounts to 31.2 million, at the current stock price of the company.

Horizon Pharma

Currently, other funds also have positive stakes in Horizon Pharma, Inc. (NASDAQ:HZNP). Thomas Steyer‘s Farallon Capital has been the most bullish, with no activity during the quarter, Holding 2.2 million shares, valued at $7.4 million. It is followed by Carl Goldsmith and Scott Klein’s Beach Point Capital Management, which was very much active in last quarter and owns over 1.88 million shares, worth $6.3 million. Meanwhile Kevin Kotler’s Broadfin Capital was a new entrant in the third quarter, reporting 1.88 million shares, worth $6.2 million.

In November, Broadfin reported boosting its stake in Horizon Pharma, Inc. (NASDAQ:HZNP). Currently, the fund holds around 3.9 million shares, which represent 5.9% of outstanding stock.

In a major development Horizon Pharma, Inc. (NASDAQ:HZNP) has been included in NASDAQ Biotechnology Index last week. NASDAQ Biotechnology Index consists of stocks which have market capitalization of $200 million and average trading volume of 100,000 shares on daily basis. Horizon Pharma, Inc. (NASDAQ:HZNP) specifically works on therapeutic needs in arthritis, pain and inflammatory diseases. Horizon Pharma, Inc. (NASDAQ:HZNP) has been rated as ‘buy’ by Zacks Equity Research in its latest report.

Disclosure: none

Recommended Reading:

Mario Gabelli Increases Position in The Marcus Corporation (MCS)

Jeff Smith Initiates 5.6% Stake and Goes Activist on Darden Restaurants, Inc. (DRI)

Blue Ridge Capital Reveals New Passive Stake in PBF Energy Inc (PBF)